The RBM10 antibody is a crucial tool for studying the RNA-binding motif protein 10 (RBM10), a multifunctional RNA-binding protein involved in regulating alternative splicing, mRNA stability, and apoptosis. RBM10 contains conserved domains, including RNA recognition motifs (RRMs) and a zinc finger domain, enabling interactions with RNA and protein partners. It plays a tumor-suppressive role in various cancers, such as lung adenocarcinoma, by modulating splicing of genes like NUMB and FAS to inhibit uncontrolled cell proliferation. Mutations in RBM10 are also linked to TARP syndrome, a rare X-linked developmental disorder.
RBM10 antibodies, typically raised in rabbits or mice, are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect RBM10 expression and localization in tissues or cell lines. These antibodies help researchers investigate RBM10's role in splicing dysregulation during carcinogenesis or its interaction with other proteins (e.g., p53). Validated antibodies are essential for ensuring specificity, as RBM10 shares homology with its paralog RBM5. Recent studies highlight its dual role in cancer—acting as either an oncogene or tumor suppressor depending on context—making RBM10 antibodies vital for both basic research and clinical diagnostics.